Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 13, 2005

View Archived Issues

Preclinical data on EP4 receptor agonist ONO-4819

LXR - a novel therapeutic target for MS

Endocannabinoid improves clinical scores in MS mice

Imatinib mesylate - a novel strategy for pulmonary hypertension/News in Context

ISIS-3082 prevents postoperative ileus in vivo

A role for Src in lung cancer

Beneficial use of NO boosting agents for atherosclerosis

Callisto and Institute of Hepatitis Viral Research collaborate on biowarfare vaccines

Avidex licenses diabetes target from King's College London

Angiotech completes acquisition of Afmedica

FDA issues health alert over Menactra

MorphoSys begins new therapeutic antibody programs with Schering

Alpharma to study abuse-resistant extended-release opioid in phase II study

Enrollment makes good progress in phase IIb colorectal cancer study of CoFactor

Agensys and sanofi pasteur collaborate on colorectal and prostate cancer vaccines

M-Vax for melanoma launched in Switzerland

Blopress receives Japanese approval for chronic heart failure

Banyu obtains Japanese import approval for Propecia

Recent patents report new treatments for respiratory disorders

Purdue Research Foundation patents novel diagnostic agents

Recent patents describe novel antiinfective agents

Extension studies of asoprisnil to be amended

Cannabis-based medicine reduces central pain scores in MS patients

Good safety profile found for topical pimecrolimus in infants with atopic dermatitis

Snapshots on studies reported at the 2005 ASBMR and NAMS meetings

Eszopiclone shows efficacy in insomnia associated with menopause

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.